Proteomic study of benign and malignant pleural effusion

Area of Science:

• Proteomics
• Biomarker Discovery
• Medical Diagnostics

Background:

• Lung adenocarcinoma frequently leads to malignant pleural effusion, which is difficult to differentiate from benign effusions.
• Current diagnostic methods lack sufficient sensitivity and specificity for malignant pleural effusion.

Purpose of the Study:

• To utilize proteomics to analyze protein profiles in benign and malignant pleural effusions.
• To identify protein biomarkers with diagnostic value for malignant pleural effusion.
• To establish a diagnostic model for differentiating pleural effusion types.

Main Methods:

• Peptide purification using weak cationic-exchanger magnetic beads (WCX-MB).
• Peptide expression profiling via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS).
• Diagnostic model development and validation using a genetic algorithm (GA).

Main Results:

• A GA diagnostic model achieved 100% sensitivity and specificity in the training set (25 malignant, 26 benign samples).
• Validation in an independent set (58 malignant, 34 benign samples) showed 89.6% sensitivity and 88.2% specificity.
• Isoform 1 of caspase recruitment domain-containing protein 9 (CARD9) at 3930.9 m/z was identified as a decreased peptide biomarker in malignant pleural effusion.

Conclusions:

• The developed model effectively discriminates between benign and malignant pleural effusion.
• CARD9 shows promise as a novel peptide biomarker for malignant pleural effusion.